01729nas a2200385   4500000000100000000000100001008004100002260001500043100001900058700001700077700001300094700002200107700001900129700001900148700002100167700001800188700002000206700002800226700001900254700002000273700001900293700002800312700002300340700002000363700001700383700002600400700001800426700002100444245007700465856004700542300000800589490000700597520072500604022001401329       2022                            d  c2022-11-261 aGautam Mahajan1 aErin Doherty1 aTania To1 aArlene Sutherland1 aJennifer Grant1 aAbidemi Junaid1 aAakanksha Gulati1 aNina LoGrande1 aZohreh Izadifar1 aSanjay Sharma Timilsina1 aViktor Horvath1 aRoberto Plebani1 aMichael France1 aIndriati Hood-Pishchany1 aSeth Rakoff-Nahoum1 aDouglas S. Kwon1 aGirija Goyal1 aRachelle Prantil-Baun1 aJacques Ravel1 aDonald E. Ingber00aVaginal microbiome-host interactions modeled in a human vagina-on-a-chip  uhttps://doi.org/10.1186/s40168-022-01400-1  a2010 v103 aA dominance of non-iners Lactobacillus species in the vaginal microbiome is optimal and strongly associated with gynecological and obstetric health, while the presence of diverse obligate or facultative anaerobic bacteria and a paucity in Lactobacillus species, similar to communities found in bacterial vaginosis (BV), is considered non-optimal and associated with adverse health outcomes. Various therapeutic strategies are being explored to modulate the composition of the vaginal microbiome; however, there is no human model that faithfully reproduces the vaginal epithelial microenvironment for preclinical validation of potential therapeutics or testing hypotheses about vaginal epithelium-microbiome interactions.  a2049-2618